Topic cluster
GLP-1 Lifestyle, Body Composition & Long-Term Outcomes
Patients on GLP-1 therapy need more than dosing instructions — they need evidence on what to eat, how much protein, what kind of exercise preserves lean mass, why their weight loss has plateaued, how the drug interacts with antidepressants and alcohol, and how it compares to bariatric surgery and older weight-loss medications. This cluster consolidates the lifestyle, body composition, and long-term outcomes literature.
11 research articles in this cluster · last updated 2026-04-08
What to Eat on a GLP-1: The Protein, Hydration, and Fiber Guide for Semaglutide and Tirzepatide
GLP-1 therapy reduces caloric intake automatically — but the remaining calories you eat still matter enormously. This guide walks through the evidence-based protein target for lean mass preservation, the fiber and hydration targets that reduce GI side effects, the foods that commonly trigger GI side effects, and how to actually eat during the slow-loss plateau phase.
Exercise on a GLP-1: Pilates, Walking, HIIT, and Resistance Training for Lean Mass Preservation
12,700+ monthly searches ask which exercise modalities work for weight loss — pilates, yoga, walking, running, HIIT, strength training. We walk through the GLP-1-specific evidence anchored on the S-LiTE trial (Lundgren NEJM 2021), the Cava 2017 lean mass preservation review, ACSM position stands, and the Saint-Maurice 2020 step count cohort, and explain why resistance training plus protein is the single highest-leverage intervention for GLP-1 patients.
Semaglutide and Muscle Mass: What the STEP Trial Sub-Analyses Actually Show
Lean body mass loss is the most underreported side effect of GLP-1 weight loss. We summarize the STEP-1 DEXA sub-analysis and what it means for older adults and resistance-trained patients.
Loose Skin After Rapid GLP-1 Weight Loss: What the Evidence Actually Shows (And What Helps)
Loose skin after rapid GLP-1 weight loss is one of the most-searched patient questions, with 15,000+ monthly queries. We walk through the dermatology and plastic surgery evidence — collagen and elastin remodeling (Rocha 2021, Light 2010), the rate-of-loss risk factor (Hasanbegovic 2013), the protein and resistance training data that mitigates lean-mass loss (Longland 2016, PROT-AGE 2013), GLP-1 trial body composition substudies, the oral collagen peptide RCT (Proksch 2014), and what the body-contouring literature says about timing and outcomes.
Why Am I Not Losing Weight on Semaglutide or Tirzepatide? The Plateau and Non-Responder Guide
Roughly 10-15% of patients in the STEP-1 and SURMOUNT-1 trials did not lose meaningful weight on GLP-1 therapy. We walk through the documented causes of non-response, the early-titration vs late-plateau distinction, injection technique and dose math errors, and the evidence-based next steps when the scale stops moving.
How Long Does Semaglutide & Tirzepatide Take to Work?
When does appetite suppression actually start on a GLP-1? When do patients first see the scale move? When does steady state hit? We answer every onset and time-to-effect question using the published STEP-1, SURMOUNT-1, and FDA prescribing information data, with the actual trial timing curves quoted by week.
GLP-1 Drugs and Alcohol Use Disorder: What the Trial Evidence Actually Shows in 2026
TikTok and the lay press have run far ahead of the trial evidence on semaglutide for alcohol cravings. We walk through the actual literature — exactly one completed Phase 2 RCT (Hendershot 2025, n=48), one ongoing Phase 2 protocol, the preclinical animal evidence, the mesolimbic dopamine mechanism, and the head-to-head against the three FDA-approved AUD medications (naltrexone, acamprosate, disulfiram).
Antidepressants and Weight on a GLP-1: SSRIs, SNRIs, Wellbutrin, and What the Evidence Actually Shows
21,000+ monthly searches ask whether SSRIs, SNRIs, and Wellbutrin cause or prevent weight loss — and how they interact with semaglutide and tirzepatide. Anchored on Gafoor 2018 BMJ (n=294,719), Anderson 2002 (bupropion +weight loss), Greenway 2010 Lancet (Contrave COR-I), the EMA PRAC 2024 review, Wang 2024 Nature Medicine, and the FDA labels for Wegovy, Ozempic, Mounjaro, Zepbound, and Foundayo.
Metformin and Non-GLP-1 Diabetes Drugs for Weight Loss: What the Trials Actually Show
26,000+ monthly searches ask whether metformin causes weight loss. The DPP, DPPOS 15-year follow-up, ADOPT, and Seifarth 2013 trials show metformin produces ~2-3 kg over 1-2 years and ~5.6% over 6 months in non-diabetic obesity — real but modest, and roughly 1/5 the magnitude of semaglutide and 1/7 of tirzepatide. Here is the verified evidence with PMIDs.
Topamax, Qsymia, and Topiramate for Weight Loss: What the Trials Actually Show
7,600+ monthly searches ask about topiramate dosing for weight loss. Anchored on Bray 2003 (-6.3% at 192-384 mg), Astrup 2004 (-16.5% at 192 mg maintenance), the Qsymia Phase 3 program (CONQUER -10.2 kg, EQUIP -10.9%, SEQUEL 108-week -12.1%), and the FDA label including the cognitive 'dopamax' side effect, kidney stone risk, metabolic acidosis, and the cleft palate teratogenicity that mandates the REMS program.
Bariatric Surgery vs GLP-1s in 2026: Cost, Insurance Coverage, and Long-Term Outcomes
9,650+ monthly searches ask whether bariatric surgery or GLP-1 receptor agonists are the right answer for obesity. We walk through the NIH 1991 and ASMBS 2022 eligibility criteria, the STAMPEDE trial (Schauer 2017), SLEEVEPASS and SM-BOSS, the Swedish Obese Subjects long-term mortality data (Sjöström 2007), the Adams 2007 NEJM cohort, the SPLENDID cancer outcomes (Aminian 2022), Medicare NCD 100.1, and the cost reality.